These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6667349)

  • 1. Prognostic value of estrogen and progesterone receptors in primary breast cancer.
    Saez S; Cheix F; Asselain B
    Breast Cancer Res Treat; 1983; 3(4):345-53. PubMed ID: 6667349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
    Vollenweider-Zerargui L; Barrelet L; Wong Y; Lemarchand-Béraud T; Gómez F
    Cancer; 1986 Mar; 57(6):1171-80. PubMed ID: 3943040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
    Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG
    Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
    Bardou VJ; Arpino G; Elledge RM; Osborne CK; Clark GM
    J Clin Oncol; 2003 May; 21(10):1973-9. PubMed ID: 12743151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer.
    Nomura Y; Tashiro H; Shinozuka K
    Cancer; 1985 Feb; 55(3):546-51. PubMed ID: 3965108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group.
    Bernoux A; de Cremoux P; Lainé-Bidron C; Martin EC; Asselain B; Magdelénat H
    Breast Cancer Res Treat; 1998 Jun; 49(3):219-25. PubMed ID: 9776505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of estrogen and progesterone receptors in stage II breast cancer.
    Rydén S; Fernö M; Borg A; Hafström L; Möller T; Norgren A
    J Surg Oncol; 1988 Apr; 37(4):221-6. PubMed ID: 3283457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.
    Chan M; Chang MC; González R; Lategan B; del Barco E; Vera-Badillo F; Quesada P; Goldstein R; Cruz I; Ocana A; Cruz JJ; Amir E
    PLoS One; 2015; 10(7):e0132449. PubMed ID: 26161666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
    Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
    Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
    Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traoré ZC; Kouyate M
    BMC Cancer; 2017 Feb; 17(1):115. PubMed ID: 28173783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with prognosis in human breast cancer. IV. Progesterone receptors and clinical factors.
    Macías A; Pascual MR; Pérez R; Lage A
    Neoplasma; 1983; 30(5):593-601. PubMed ID: 6656963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen and progesterone receptors as prognostic factors in breast cancer.
    Brdar B; Graf D; Padovan R; Nola P; Rudan N; Petrinec Z; Sarcević B; Belicza M
    Tumori; 1988 Feb; 74(1):45-52. PubMed ID: 3354064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.